The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association

Jae Hoon Moon; Ka Hee Yi

doi:10.3803/EnM.2013.28.4.275

Articles

Page Path: HOME > Endocrinol Metab > Volume 28(4); 2013 > Article

Review Article The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association: Jae Hoon Moon¹, Ka Hee Yi²; Endocrinology and Metabolism 2013;28(4):275-279.
DOI: https://doi.org/10.3803/EnM.2013.28.4.275
Published online: December 12, 2013

¹Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

²Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.

Corresponding author: Ka Hee Yi. Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 156-707, Korea. Tel: +82-2-870-3203, Fax: +82-2-870-3866, khyi@snu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

6,036 Views
76 Download
54 Crossref

prev next

Full Article

Download PDF

ABSTRACT
INTRODUCTION
DIAGNOSIS OF HYPERTHYROIDISM IN KOREA
TREATMENT OF HYPERTHYROIDISM DUE TO GRAVES DISEASE IN KOREA
CONCLUSIONS
Article information
References

ABSTRACT

Hyperthyroidism is one of the causes of thyrotoxicosis and the most common cause of hyperthyroidism in Korea is Graves disease. The diagnosis and treatment of Graves disease are different according to geographical area. Recently, the American Thyroid Association and the American Association of Clinical Endocrinologists suggested new management guidelines for hyperthyroidism. However, these guidelines are different from clinical practice in Korea and are difficult to apply. Therefore, the Korean Thyroid Association (KTA) conducted a survey of KTA members regarding the diagnosis and treatment of hyperthyroidism, and reported the consensus on the management of hyperthyroidism. In this review, we summarized the KTA report on the contemporary practice patterns in the diagnosis and management of hyperthyroidism, and compared this report with guidelines from other countries.
Keywords: Consensus; Diagnosis; Graves disease; Hyperthyroidism; Management

INTRODUCTION

Thyrotoxicosis, which is defined as all clinical statuses resulting from thyroid hormone excess in peripheral blood and tissues, is divided into two major categories by etiology: the presence or absence of accompanying hyperthyroidism. The most common cause of thyrotoxicosis in Korea is Graves disease (82.7%), followed by subacute thyroiditis (13.3%), painless thyroiditis (3.5%), and toxic adenoma (0.5%) [1]. Familial or sporadic nonautoimmune hyperthyroidism due to the germline mutation in the thyroid stimulating hormone (TSH) receptor is a rare cause of thyrotoxicosis and should be differentiated from Graves disease [2].

Graves disease is an autoimmune disorder in which TSH receptor antibodies stimulate the thyroid gland and result in hyperthyroidism, diffuse goiter, ophthalmopathy, and dermopathy. The treatment of Graves disease includes antithyroid medication, ¹³¹I therapy, and thyroidectomy. Numerous medical and nonmedical factors, including patient compliance, age, size of goiter, symptom severity, patient socioeconomic status, experience and preference of physicians and surgeons, and availability of medical facilities for ¹³¹I therapy, affect the choice of treatment modality. In addition, the most preferred treatment differs from country to country according to the medical insurance system, medical expenses, and patients reluctance to be exposed to radioactive material or surgery.

Recently, the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) published new management guidelines for hyperthyroidism [3]. However, these guidelines are quite different from clinical practice in Korea and are difficult to apply. Therefore, the Korean Thyroid Association (KTA) conducted a survey of KTA members regarding the diagnosis and treatment of hyperthyroidism, and subsequently reported the consensus on the management of hyperthyroidism [4]. In this review, we summarized the KTA consensus report on the management of hyperthyroidism and compared it with guidelines from other countries.

DIAGNOSIS OF HYPERTHYROIDISM IN KOREA

When hyperthyroidism is strongly suspected, the KTA guidelines suggest measurement of both serum TSH and free thyroxine (T4) levels at the time of the initial evaluation [4]. The total triiodothyronine (T3) measurement is helpful for the diagnosis of T3-toxicosis. If serum TSH is normal and free T4 is elevated, TSH-producing pituitary adenoma and thyroid hormone resistance should be considered. Euthyroid hyperthyroxinemia is mostly due to thyroid hormone-binding protein disorders that cause elevated total T4 and normal TSH concentrations in the absence of hyperthyroidism [5]. A pituitary lesion on magnetic resonance imaging and a high serum level of TSH α-subunit support the diagnosis of a TSH-producing pituitary adenoma [6]. A family history and positive result of genetic testing for mutations in the T3-receptor gene support a diagnosis of thyroid hormone resistance [7].

The severity of thyrotoxic symptoms is inversely correlated with age [8]; therefore, cardiac evaluation, including electrocardiogram, echocardiogram, Holter monitor, or the myocardiac perfusion test, may be required for the diagnosis and treatment of ischemic heart disease, congestive heart failure, or atrial arrhythmias in older patients [9].

For the determination of etiology, the KTA report remarked on the usefulness of an anti-TSH receptor antibody (TRAb) assay for the diagnosis of Graves disease [4]. A second-generation thyrotropin-binding inhibitor immunoglobulin assay, which utilizes human recombinant TSH receptors, showed a specificity of 99% and a sensitivity of 95% for the diagnosis of Graves disease [10]. The ATA/AACE guidelines strongly recommend radioactive iodine uptake test when the clinical presentation of thyrotoxicosis is not diagnostic of Graves disease, and also suggest adding a thyroid scan in the presence of thyroid nodularity [3]. In contrast, only 37% (50/137) of KTA members responded that they perform a thyroid uptake test and 61% (83/137) use a thyroid scan for the diagnosis of hyperthyroidism. Furthermore, most of KTA members (92%, 70/76) use ^99mTcO4 rather than ¹²³I or ¹³¹I for a thyroid uptake test or thyroid scan. A TRAb assay is used by 94.5% (129/137) of KTA members for the diagnosis of Graves disease. These results show that a TRAb assay is mainly used for the determination of etiology in thyrotoxicosis, and this trend is also shown in Europe and Japan. On the other hand, the ATA/AACE guidelines suggest a TRAb assay and the ratio of total T3 to total T4 as an alternative method of diagnosing Graves disease when a thyroid scan and uptake are unavailable or contraindicated [3,11]. Color Doppler ultrasonography is used by only 16.8% (23/137) of KTA members to diagnose hyperthyroidism, whereas Doppler flow is generally used in Europe and Japan [12].

For the symptomatic management of thyrotoxicosis, the KTA report recommends β-adrenergic blockade [4]. Once it has been established that a patient has hyperthyroidism caused by Graves disease, the initial treatment options are an antithyroid drug (ATD), ¹³¹I therapy (radioactive iodine), and thyroidectomy. In the United States, radioactive iodine has been the most preferred therapy, whereas there has been a greater physician preference for ATDs in Europe and Japan [13]. In the KTA survey, 97.1% (133/137) of KTA members reported choosing ATDs and remaining 2.9% (4/137) chose radioactive iodine for the initial treatment. The ATA/AACE guidelines recommend that the treating physician and patient should discuss each of the treatment options, including the logistics, benefits, expected speed of recovery, drawbacks, potential side effects, and cost [3]. The long-term quality of life after initial treatment for Graves disease was not different among the three treatment options [14]. The KTA report suggests suitable indications and contraindications for each treatment option.
Antithyroid drugs: Although ATDs have been employed for six decades [15] and are very effective in controlling hyperthyroidism, these medications do not cure Graves disease. Their major effect is to reduce thyroid hormone synthesis and maintain a euthyroid state while awaiting spontaneous remission. The KTA report recommends methimazole or carbimazole for patients who choose ATD therapy for Graves disease, except during the first trimester of pregnancy, in the treatment of thyroid storm, and in patients with minor reactions to methimazole or carbimazole who refuse radioactive iodine therapy or surgery [4]. In practice, methimazole was chosen as an initial ATD by 85.5% (112/131) of KTA members. Prophylthiouracil (PTU) and carbimazole were chosen by 9.9% (13/131) and 4.3% (6/131) of KTA members, respectively. The KTA report advises higher doses of ATDs at the start of medication (methimazole, 10 to 20 mg daily; PTU, 50 to 150 mg three times daily) to restore euthyroidism, and the titration to a maintenance level (methimazole, 5 to 10 mg daily; PTU, 50 mg two or three times daily) [4]. The KTA report strongly emphasizes notifying all patients of the side effects of ATDs and proper management for the side effects, including agranulocytosis and hepatotoxicity [4]. Monitoring strategies for patients using ATDs are also suggested.; If serum TSH, free T4, and T3 levels have been maintained within normal ranges for 1 year after discontinuation of ATD therapy, remission can be considered. The remission rate varies between geographical areas. In the United States, the remission rate is approximately 20% to 30% after 12 to 18 months of medication [16], whereas a long-term European study showed a 50% to 60% remission rate after 5 to 6 years of ATD treatment [17]. In Japan, maintenance of a minimal dose of ATDs (methimazole, 2.5 mg daily) longer than 6 months after the normalization of TSH is recommended for a higher remission rate [18]. However, a meta-analysis showed that the maintenance of ATDs longer than 18 months did not improve the remission rate in adults [19]. ATDs are discontinued after the normalization of both serum TSH and TRAb by 60% to 70% of KTA members. About 30% of respondents answered that they use ATDs for a fixed duration, most frequently for 12 to 24 months. In case of the recurrence after ATD treatment, 46.9% (60/128) of KTA members chose ATDs again for the treatment of Graves disease; while radioactive iodine and thyroidectomy were chosen by 48.4% (62/128) and 4.7% (6/128) of KTA members, respectively. In Korea, ATDs are the most preferred modality for retreatment as well as initial treatment, and the treatment duration of ATDs is longer compared with other countries.
Radioactive iodine: ¹³¹I has been used to treat hyperthyroidism for six decades. This therapy is well tolerated with rare complications, except for those related to ophthalmopathy. The KTA report recommends that the use of methimazole or β blockades before and after ¹³¹I treatment may be considered in patients with severe thyrotoxicosis [4]. The ATA/AACE guidelines remark that if given as pretreatment, methimazole should be discontinued 3 to 5 days before the administration of radioactive iodine, restarted 3 to 7 days later, and generally tapered over 4 to 6 weeks as thyroid function normalizes [3]. In the KTA survey, ATDs were used before and after ¹³¹I treatment by 56% and 43% of KTA members, respectively.; Although the ATA/AACE guidelines do not recommend a special diet before ¹³¹I therapy, excessive iodine intake should be avoided for at least 7 days before treatment. Because daily intake of iodine is more than 500 µg in Korea, the need for a special diet before ¹³¹I treatment should be validated in future studies.; Administering a fixed ¹³¹I activity or calculating the activity based on the size of the thyroid and its ability to trap iodine showed no difference in controlling hyperthyroidism by rendering the patient hypothyroid [16]. The KTA report recommends sufficient radiation (10 to 15 mCi) in a single dose [4]. A pregnancy test should be obtained within 48 hours prior to treatment in any female with childbearing potential [4].; After radioactive iodine therapy for Graves disease, a follow-up thyroid function test should be performed within the first 1 to 2 months. If the patient remains thyrotoxic, biochemical monitoring should be continued at 4 to 6 week intervals [4]. The KTA report recommends retreatment with ¹³¹I when hyperthyroidism persists after 6 months following ¹³¹I therapy, or if there is minimal response 3 months after therapy [4].
Surgery: Thyroidectomy is rarely chosen for treatment of Graves disease in Korea. The KTA report recommends near-total or total thyroidectomy as the procedure of choice [4]. The optimal preparation for thyroidectomy, the monitoring and treatment strategy for the possible complications, and postoperative management, including T4 replacement, are described in the KTA report [4].

CONCLUSIONS

The KTA consensus report was based on the ATA/AACE guidelines, and therefore, the recommendations are similar. However, the KTA consensus report was also based on a survey of KTA members and is therefore more suitable for clinical practice in Korea. In addition, the recommendations in the KTA consensus report are limited to the treatment of Graves disease, because other causes of hyperthyroidism are relatively rare and the treatment of those diseases does not differ according to geographical area. Considering the differences in the clinical practice patterns in the diagnosis and treatment of hyperthyroidism in Korea compared with other countries, further studies investigating the characteristics and optimal treatment of hyperthyroidism in Korean patients and the consequential revision of the KTA report are needed.

Article information

No potential conflict of interest relevant to this article was reported.

References

1. Cho BY. Clinical thyroidology; 3rd ed. Seoul: Korea Medical Book Publisher; 2010.
2. Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol 2010;322:125–134. Article PubMed
3. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. American Thyroid Association. American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593–646. Article PubMed
4. Yi KH, Moon JH, Kim IJ, Bom HS, Lee J, Chung WY, Chung JH, Shong YK. The diagnosis and management of hyperthyroidism consensus: report of the Korean Thyroid Association. J Korean Thyroid Assoc 2013;6:1–11.Article PDF
5. Rajatanavin R, Liberman C, Lawrence GD, DArcangues CM, Young RA, Emerson CH. Euthyroid hyperthyroxinemia and thyroxine-binding prealbumin excess in islet cell carcinoma. J Clin Endocrinol Metab 1985;61:17–21. Article PubMed PDF
6. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003;148:433–442. Article PubMed
7. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD. The National Institutes of Health Prospective Study. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. Ann Intern Med 1995;123:572–583. Article PubMed
8. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010;95:2715–2726. Article PubMed PDF
9. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116:1725–1735. Article PubMed
10. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf) 2001;55:381–390. Article PubMed
11. Shigemasa C, Abe K, Taniguchi S, Mitani Y, Ueda Y, Adachi T, Urabe K, Tanaka T, Yoshida A, Mashiba H. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves' disease despite similar serum total T4 levels. J Clin Endocrinol Metab 1987;65:359–363. Article PubMed PDF
12. Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab 2008;4:70–71. Article PubMed PDF
13. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129–135. Article PubMed
14. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005;15:1279–1286. Article PubMed
15. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905–917. Article PubMed
16. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121:281–288. Article PubMed
17. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole: comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008;31:866–872. Article PubMed PDF
18. The Japan Thyroid Association. Guideline for the treatment of Graves' disease with antithyroid drug in Japan; Tokyo: Nankodo Co., Ltd.; 2006.
19. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005;153:489–498. Article PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Effects of altitude on thyroid disorders according to Chinese three-rung, ladder-like topography: national cross-sectional study
Boshen Gong, Youmin Wang, Jin-an Zhang, Qiao Zhang, Jiajun Zhao, Jiashu Li, Xichang Wang, Yutong Han, Ziwei Yu, Chenyu Zhang, Bingcong Peng, Yumin Xing, Qiuxian Li, Ping Wang, Yongze Li, Weiping Teng, Zhongyan Shan
BMC Public Health.2024;[Epub] CrossRef
MACE and Hyperthyroidism Treated With Medication, Radioactive Iodine, or Thyroidectomy
Carol Chiung-Hui Peng, Yu-Jie Lin, Sun Y. Lee, Shu-Man Lin, Cheng Han, Ching-Hui Loh, Huei-Kai Huang, Elizabeth N. Pearce
JAMA Network Open.2024; 7(3): e240904. CrossRef
Increased risk of incident gout in patients with hyperthyroidism: a nationwide retrospective cohort study
Ju-Yeun Lee, So-Yeon Park, Seo Young Sohn
Rheumatology International.2023; 44(3): 451. CrossRef
The Current Status of Hyperthyroidism in Korea
Hyemi Kwon
Endocrinology and Metabolism.2023; 38(4): 392. CrossRef
Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas
Mika Tamura, Kunihiro Nakada, Haruna Iwanaga, Naotoshi Fujita, Katsuhiko Kato
European Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub] CrossRef
A machine learning-assisted system to predict thyrotoxicosis using patients’ heart rate monitoring data: a retrospective cohort study
Kyubo Shin, Jongchan Kim, Jaemin Park, Tae Jung Oh, Sung Hye Kong, Chang Ho Ahn, Joon Ho Moon, Min Joo Kim, Jae Hoon Moon
Scientific Reports.2023;[Epub] CrossRef
Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease
Daiki Setoyama, Ho Yeop Lee, Ji Sun Moon, Jingwen Tian, Yea Eun Kang, Ju Hee Lee, Minho Shong, Dongchon Kang, Hyon‐Seung Yi
Journal of Cachexia, Sarcopenia and Muscle.2022; 13(1): 355. CrossRef
Comparison of 99mTc Pertechnetate Thyroid Uptake Rates by Gamma Probe and Gamma Camera Methods for Differentiating Graves’ Disease and Thyroiditis
Meihua Jin, Jonghwa Ahn, Seong-gil Jo, Jangwon Park, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jin-Sook Ryu
Nuclear Medicine and Molecular Imaging.2022; 56(1): 42. CrossRef
KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2022; 56(1): 17. CrossRef
Graves’ disease and the risk of Parkinson’s disease: a Korean population-based study
Yoon Young Cho, Bongseong Kim, Dong Wook Shin, Jinyoung Youn, Ji Oh Mok, Chul-Hee Kim, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Brain Communications.2022;[Epub] CrossRef
Graves’ Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Study
Yoon Young Cho, Bongseong Kim, Dong Wook Shin, Hye Ryoun Jang, Bo-Yeon Kim, Chan-Hee Jung, Jae Hyeon Kim, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Endocrinology and Metabolism.2022; 37(2): 281. CrossRef
Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang
International Journal of Thyroidology.2022; 15(1): 1. CrossRef
Patient Population and Test Utilization for Thyroid Function in Local Clinics and Hospitals in Korea
Rihwa Choi, Sang Gon Lee, Eun Hee Lee
Diagnostics.2022; 12(7): 1638. CrossRef
2021 Asia-Pacific Graves’ Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves’ Disease
Rajeev Parameswaran, Mechteld Christine de Jong, James Lee Wai Kit, Kathleen Sek, Tran Quang Nam, Tran Viet Thang, Nguyen Thy Khue, Than Than Aye, Phone Myint Tun, Timothy Cole, Julie A. Miller, Michael Villa, Benjapa Khiewvan, Sirinart Sirinvaravong, Yon
Endocrine.2022; 79(1): 135. CrossRef
Graves’ disease, its treatments, and the risk of atrial fibrillation: A Korean population-based study
Yoon Young Cho, Bongseong Kim, Dughyun Choi, Chul-Hee Kim, Dong Wook Shin, Jee Soo Kim, Seung-Jung Park, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Frontiers in Endocrinology.2022;[Epub] CrossRef
Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek
Endocrinology and Metabolism.2022; 37(6): 851. CrossRef
Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis
Carolina M. Perdomo, Marta García‐Goñi, Lidia Sancho, José J. Paricio, María D. Lozano, Magdalena de la Higuera, María Currás, Javier Arbizu, Juan C. Galofré
Clinical Endocrinology.2021; 94(3): 466. CrossRef
Treatment of patients with Graves’ disease in Sweden compared to international surveys of an ‘index patient’
Gabriel Sjölin, Kristina Byström, Mats Holmberg, Ove Törring, Selwan Khamisi, Jan Calissendorff, Mikael Lantz, Bengt Hallengren, Helena Filipsson Nyström, Tereza Planck, Göran Wallin
Endocrinology, Diabetes & Metabolism.2021;[Epub] CrossRef
Secular Trends in Ablation Therapy for Graves’ Disease: An Analysis of a 15-Year Experience at a Tertiary Hospital in South Korea
Min Joo Kim, Ye An Kim, Sun Wook Cho, Su-jin Kim, Kyu Eun Lee, Young Joo Park, Do Joon Park, Bo Youn Cho
Journal of Clinical Medicine.2021; 10(8): 1629. CrossRef
Long-Term Antithyroid Drug Treatment of Graves’ Disease in Children and Adolescents: A 20-Year Single-Center Experience
Ari Song, Su Jin Kim, Min-Sun Kim, Jiyeon Kim, Insung Kim, Ga Young Bae, Eunseop Seo, Young Seok Cho, Joon Young Choi, Sung Yoon Cho, Dong-Kyu Jin
Frontiers in Endocrinology.2021;[Epub] CrossRef
Association of Polygenetic Risk Scores Related to Immunity and Inflammation with Hyperthyroidism Risk and Interactions between the Polygenetic Scores and Dietary Factors in a Large Cohort
Mi Young Song, Sunmin Park, Anjali Mishra
Journal of Thyroid Research.2021; 2021: 1. CrossRef
Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves’ Disease: A Nationwide Population-Based Cohort Study
Eyun Song, Mina Kim, Sojeong Park, Min Jeong Park, Jung A. Kim, Eun Roh, Ji Hee Yu, Nam Hoon Kim, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Frontiers in Endocrinology.2021;[Epub] CrossRef
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Endocrinology and Metabolism.2021; 36(6): 1277. CrossRef
Diabetes and Hyperthyroidism: Is There a Causal Link?
Sang Yong Kim
Endocrinology and Metabolism.2021; 36(6): 1175. CrossRef
Incidence and Mortality of Myocardial Infarction and Stroke in Patients with Hyperthyroidism: A Nationwide Cohort Study in Korea
Hyun Jung Kim, Taeuk Kang, Min Ji Kang, Hyeong Sik Ahn, Seo Young Sohn
Thyroid.2020; 30(7): 955. CrossRef
Diagnosis and Management of Graves’ Disease in Thailand: A Survey of Current Practice
Chutintorn Sriphrapradang
Journal of Thyroid Research.2020; 2020: 1. CrossRef
The success rate of radioactive iodine therapy for Graves’ disease in iodine-replete area and affecting factors: a single-center study
Hyunju Park, Hye In Kim, Jun Park, So Young Park, Tae Hyuk Kim, Jae Hoon Chung, Joon Young Choi, Sun Wook Kim
Nuclear Medicine Communications.2020; 41(3): 212. CrossRef
Tirotoksikoz nedenli erektil disfonksiyon üzerine sildenafil etkisinin histopatolojik olarak değerlendirilmesi
Murat ÖZDEMİR, Canberk TOMRUK, Gürkan YİĞİTTÜRK, Varlık EROL, Emel Öykü ÇETİN, Ilgın YILDIRIM ŞİMŞİR, Çiğdem YENİSEY, Yiğit UYANIKGİL, Adnan ŞİMŞİR, Özer MAKAY
Ege Tıp Dergisi.2020; 59(3): 215. CrossRef
The Management of Thyroid Disease in COVID-19 Pandemic
Won Sang Yoo, Hyun-Kyung Chung
International Journal of Thyroidology.2020; 13(2): 65. CrossRef
Is Hyperthyroidism Diagnosed and Treated Appropriately in the United States?
Ammar Asban, Sophie Dream, Brenessa Lindeman
Advances in Surgery.2019; 53: 117. CrossRef
Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value
Ricardo V. García-Mayor, Paula Álvarez-Vázquez, Enrique Fluiters, Diana Valverde, Amalia Andrade
Endocrine.2019; 63(2): 316. CrossRef
Safety of long-term antithyroid drug treatment? A systematic review
F. Azizi, R. Malboosbaf
Journal of Endocrinological Investigation.2019; 42(11): 1273. CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268. CrossRef
Prevalence and Annual Incidence of Thyroid Disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study
Hyemi Kwon, Jin-hyung Jung, Kyung-Do Han, Yong-Gyu Park, Jung-Hwan Cho, Da Young Lee, Ji Min Han, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2018; 33(2): 260. CrossRef
An update in the treatment preference for hyperthyroidism
Obin Kwon
Nature Reviews Endocrinology.2018; 14(7): 438. CrossRef
Clinical Feasibility of Monitoring Resting Heart Rate Using a Wearable Activity Tracker in Patients With Thyrotoxicosis: Prospective Longitudinal Observational Study
Jie-Eun Lee, Dong Hwa Lee, Tae Jung Oh, Kyoung Min Kim, Sung Hee Choi, Soo Lim, Young Joo Park, Do Joon Park, Hak Chul Jang, Jae Hoon Moon
JMIR mHealth and uHealth.2018; 6(7): e159. CrossRef
Graves' Disease Patients with Large Goiters Respond Best to Radioactive Iodine Doses of at Least 15 mCi: a Sonographic Volumetric Study
Yun Ah Jeong, Jee Hee Yoon, Hee Kyung Kim, Ho-Cheol Kang
International Journal of Thyroidology.2018; 11(2): 137. CrossRef
Chylothorax Associated with Substernal Goiter in Graves’ Disease Treated with Radioactive Iodine
Seo Young Oh, Bo Hyun Kim, Do Young Kim, Kyu Min Lee, Min Jin Lee, Sung Su Kim, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Joo Kim
International Journal of Endocrinology and Metabolism.2017;[Epub] CrossRef
Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea
Jung Min Bae, June Hyunkyung Lee, Jae Seung Yun, Byeol Han, Tae Young Han
Journal of the American Academy of Dermatology.2017; 76(5): 871. CrossRef
Increased risk of thyroid diseases in patients with systemic lupus erythematosus: A nationwide population-based Study in Korea
Jae-Seung Yun, Jung Min Bae, Ki-Jo Kim, Yu Seok Jung, Gyong Moon Kim, Hyung-Rae Kim, Jun-Seok Lee, Seung-Hyun Ko, Seon-Ah Cha, Yu-Bae Ahn, Ludmila Prokunina-Olsson
PLOS ONE.2017; 12(6): e0179088. CrossRef
The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study
Ye An Kim, Sun Wook Cho, Hoon Sung Choi, Shinje Moon, Jae Hoon Moon, Kyung Won Kim, Do Joon Park, Ka Hee Yi, Young Joo Park, Bo Youn Cho
Thyroid.2017; 27(4): 491. CrossRef
Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
Hoon Sung Choi, Won Sang Yoo
Endocrinology and Metabolism.2017; 32(2): 281. CrossRef
Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis
Fereidoun Azizi, Ramin Malboosbaf
Thyroid.2017; 27(10): 1223. CrossRef
The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
Myoung Sook Shim, Soo Min Nam, Jin Sae Yoo, Hae Kyung Kim, Sang Jun Lee, Mi Young Lee
International Journal of Thyroidology.2017; 10(2): 77. CrossRef
Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence
Hwa Young Ahn, Yun Jae Chung, Bo Youn Cho
Medicine.2017; 96(31): e7700. CrossRef
Recent Advances in Autoimmune Thyroid Diseases
Won Sang Yoo, Hyun Kyung Chung
Endocrinology and Metabolism.2016; 31(3): 379. CrossRef
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(2): 300. CrossRef
Hyperthyroidism
Simone De Leo, Sun Y Lee, Lewis E Braverman
The Lancet.2016; 388(10047): 906. CrossRef
Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine
Chutintorn Sriphrapradang, Adikan Bhasipol
Annals of Medicine and Surgery.2016; 10: 69. CrossRef
Management of hyperthyroid patients in dental emergencies: a case report
Kyung-Jin Lee, Wonse Park, Nan-Sim Pang, Jin-Hyung Cho, Kee-Deog Kim, Bock Young Jung, Eun-Jung Kwak
Journal of Dental Anesthesia and Pain Medicine.2016; 16(2): 147. CrossRef
The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves’ Disease
Sun Wook Cho, Jae Hyun Bae, Gyeong Woon Noh, Ye An Kim, Min Kyong Moon, Kyoung Un Park, Junghan Song, Ka Hee Yi, Do Joon Park, June-Key Chung, Bo Youn Cho, Young Joo Park, Jung-Eun Kim
PLOS ONE.2015; 10(12): e0144599. CrossRef
Refractory Graves' Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy
Yeoree Yang, Seawon Hwang, Minji Kim, Yejee Lim, Min-Hee Kim, Sohee Lee, Dong-Jun Lim, Moo-Il Kang, Bong-Yun Cha
Endocrinology and Metabolism.2015; 30(4): 620. CrossRef
Improved quality of life in hyperthyroidism patients after surgery
Branka Bukvic, Vladan Zivaljevic, Sandra Sipetic, Aleksandar Diklic, Katarina Tausanovic, Dragos Stojanovic, Dejan Stevanovic, Ivan Paunovic
Journal of Surgical Research.2015; 193(2): 724. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef